SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and good tolerability especially in patients at ris...
Saved in:
| Main Author: | M. Ganeva |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Trakia University
2023-03-01
|
| Series: | Trakia Journal of Sciences |
| Subjects: | |
| Online Access: | http://tru.uni-sz.bg/tsj/Volume%2021,%202023,%20Number%201,%20Series%20Biomedical%20Sciences/9_M.Ganeva.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas
by: Wei‐Sheng Chen, et al.
Published: (2025-03-01) -
Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01) -
Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis
by: Adili Tuersun, PhD, et al.
Published: (2025-01-01) -
Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection
by: Yoo-Ri Chung, et al.
Published: (2025-07-01) -
Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study
by: Yu-Ching Li, et al.
Published: (2025-04-01)